NCT02294734 - An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

February 19, 2016

Study Completion Date

April 25, 2016

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK2269557

Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily

DRUG

Placebo

Dry powder for inhalation via DISKUS 'device'

Trial Locations (17)

2650

GSK Investigational Site, Edegem

GSK Investigational Site, Hvidovre

5101

GSK Investigational Site, Erpent

150003

GSK Investigational Site, Yaroslavl

194291

GSK Investigational Site, Saint Petersburg

300310

GSK Investigational Site, Timișoara

600023

GSK Investigational Site, Vladimir

620109

GSK Investigational Site, Yekaterinburg

650002

GSK Investigational Site, Kemerovo

DK-9100

GSK Investigational Site, Aalborg

DK-2400

GSK Investigational Site, Copenhagen

5000 Odense C

GSK Investigational Site, Odense

7609 PP

GSK Investigational Site, Almelo

5623 EJ

GSK Investigational Site, Eindhoven

7207 AE

GSK Investigational Site, Zutphen

050159

GSK Investigational Site, Bucharest

105 077

GSK Investigational Site, Moscow